Mark I-C Chen
Overview
Explore the profile of Mark I-C Chen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
1582
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tan C, Zhu F, Chia W, Young B, Yeoh A, Althaus T, et al.
Hlife
. 2024 Jul;
1(1):26-34.
PMID: 38994526
Multiple Omicron sub-lineages have emerged, with Omicron XBB and XBB.1.5 subvariants becoming the dominant variants globally at the time of this study. The key feature of new variants is their...
2.
Tavitian-Exley I, Hao Y, Chen M, Wong C, Kwok C, Toh M
Front Public Health
. 2024 May;
12:1330282.
PMID: 38737858
Introduction: Low-level HIV epidemic settings like Singapore face the challenge of reaching men at-risk who have less contact with programmes. We investigated patterns of meeting platform use by men seeking...
3.
Sadarangani S, Young B, Lian W, Phua H, Chen M, Barr I, et al.
NPJ Vaccines
. 2022 Nov;
7(1):135.
PMID: 36319665
Immunosenescence (age-related immune dysfunction) and inflamm-aging contribute to suboptimal immune responses in older adults to standard-dose influenza vaccines, which may be exacerbated in those with metabolic co-morbidities. We sought to...
4.
Tan C, Chia W, Zhu F, Young B, Chantasrisawad N, Hwa S, et al.
Nat Microbiol
. 2022 Oct;
7(11):1756-1761.
PMID: 36195753
The SARS-CoV-2 Omicron variant (B.1.1.529 lineage) escapes antibodies that neutralize the ancestral virus. We tested human serum panels from participants with differing infection and vaccination status using a multiplex surrogate...
5.
Tan C, Chia W, Young B, Zhu F, Lim B, Sia W, et al.
N Engl J Med
. 2021 Aug;
385(15):1401-1406.
PMID: 34407341
Emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern pose a challenge to the effectiveness of current vaccines. A vaccine that could prevent infection caused by known and...
6.
Chia W, Zhu F, Ong S, Young B, Fong S, Bert N, et al.
Lancet Microbe
. 2021 Mar;
2(6):e240-e249.
PMID: 33778792
Background: Studies have found different waning rates of neutralising antibodies compared with binding antibodies against SARS-CoV-2. The impact of neutralising antibody waning rate at the individual patient level on the...
7.
Tan C, Chia W, Qin X, Liu P, Chen M, Tiu C, et al.
Nat Biotechnol
. 2020 Jul;
38(9):1073-1078.
PMID: 32704169
A robust serological test to detect neutralizing antibodies to SARS-CoV-2 is urgently needed to determine not only the infection rate, herd immunity and predicted humoral protection, but also vaccine efficacy...
8.
Chia W, Tan C, Foo R, Kang A, Peng Y, Sivalingam V, et al.
Emerg Microbes Infect
. 2020 Jun;
9(1):1497-1505.
PMID: 32529906
In response to the coronavirus disease 2019 (COVID-19) outbreak, caused by SARS-CoV-2, multiple diagnostic tests are required for acute disease diagnosis, contact tracing, monitoring asymptomatic infection rates and assessing herd...
9.
Anderson D, Tan C, Chia W, Young B, Linster M, Low J, et al.
Emerg Microbes Infect
. 2020 May;
9(1):900-902.
PMID: 32380903
Despite initial findings indicating that SARS-CoV and SARS-CoV-2 are genetically related belonging to the same virus species and that the two viruses used the same entry receptor, angiotensin-converting enzyme 2...
10.
Pung R, Chiew C, Young B, Chin S, Chen M, Clapham H, et al.
Lancet
. 2020 Mar;
395(10229):1039-1046.
PMID: 32192580
Background: Three clusters of coronavirus disease 2019 (COVID-19) linked to a tour group from China, a company conference, and a church were identified in Singapore in February, 2020. Methods: We...